Christopher Cabell

Christopher Cabell

Net worth: 1 M $ as of 30/05/2026

57 year
Health Technology
Consumer Services
Commercial Services

Profile

Christopher H.
Cabell
is Chief Executive Officer at Corhepta Pharmaceuticals, Inc. since 2024.
Dr. Cabell is Director at ScienceMedia, Inc. since 2020.
Dr. Cabell is Independent Director at Pulmatrix, Inc. since 2020.
Dr. Cabell is a Member of the American College of Cardiology Foundation.
Dr. Cabell is President & Head-Research & Development at Inhibikase Therapeutics, Inc. starting 2025.
Formerly, Dr. Cabell was Chief Medical Officer & Executive Vice President at Zura Bio Ltd. from 2023 to 2024.
Dr. Cabell was Chief Medical Officer & Head-Clinical Development at Emergent BioSolutions, Inc. from 2021 to 2023.
Dr. Cabell was Chief Medical Officer, Head-Research & Development at Arena Pharmaceuticals, Inc. in 2020.
Dr. Cabell was Senior VP & Head-Therapeutic Delivery Unit at Quintiles Transnational Corp.
from 2015 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at Quintiles, Inc. (California) from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA RDS, Inc. from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA, Inc. Formerly, Dr. Cabell was Director at Cenduit LLC.
Dr. Cabell was Director-Echocardiography Core Lab at Duke Clinical Research Institute.
Dr. Cabell was Co-Chairman at Cardiac Safety Research Consortium.
Dr. Cabell was Co-Chairman at US Food & Drug Administration.
Dr. Cabell was Associate Professor at Duke University School of Medicine.
Education includes graduate degree from Duke University, undergraduate degree from The Pennsylvania State University, and doctorate from Duke University School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
14/04/2026 676,564 ( 0.51% ) 1 M $ 30/05/2026
22/02/2026 0 ( -.--% ) - $ 30/05/2026

Christopher Cabell active positions

CompaniesPositionStart
PULMATRIX, INC. Director/Board Member 22/06/2020
INHIBIKASE THERAPEUTICS, INC. President 20/02/2025
Director/Board Member 17/02/2020
Corporate Officer/Principal 29/04/2009

Former positions of Christopher Cabell

CompaniesPositionEnd
ZURA BIO LIMITED Chief Tech/Sci/R&D Officer 14/01/2024
EMERGENT BIOSOLUTIONS INC. Chief Tech/Sci/R&D Officer 31/12/2022
ARENA PHARMACEUTICALS Chief Tech/Sci/R&D Officer 30/11/2020
Chief Tech/Sci/R&D Officer 31/08/2017
Chief Tech/Sci/R&D Officer 21/07/2011
See the detail of Christopher Cabell's experience

Training of Christopher Cabell

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

77

1st degree connections

18

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies18

Commercial Services

Technology Services

Health Technology

Health Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Government

Health Services

Commercial Services

Technology Services

Distribution Services

Health Technology

Consumer Services

Health Technology

Cardiac Safety Research Consortium

Health Technology

  1. Stock Market
  2. Insiders
  3. Christopher Cabell